Sputum smear conversion and treatment outcomes among drug-resistant pulmonary tuberculosis patients in eastern Ethiopia: A 9-years data analysis.

Ethiopia pulmonary smear sputum treatment outcome tuberculosis

Journal

Frontiers in medicine
ISSN: 2296-858X
Titre abrégé: Front Med (Lausanne)
Pays: Switzerland
ID NLM: 101648047

Informations de publication

Date de publication:
2022
Historique:
received: 09 08 2022
accepted: 08 11 2022
entrez: 19 12 2022
pubmed: 20 12 2022
medline: 20 12 2022
Statut: epublish

Résumé

Drug-resistant tuberculosis (DR-TB) has become a public health problem throughout the world and about one-third of deaths were attributed to DR-TB from antimicrobial resistance which contributes to 10% of all TB deaths. Sub-Saharan Africa, particularly Ethiopia accounts for a significant number of TB cases. However, the scanty evidence on DR-TB contributing factors could affect the level of this deadly case tackling program. Therefore, this study aimed to assess the factors affecting sputum smear conversion and treatment outcomes among patients with DR-TB in Health facilities in Eastern Ethiopia. A cross-sectional study design was employed from 10 October to 10 November 2021, in the health facilities providing DR-TB services in Harari Region and Dire Dawa city administration. The medical records of 273 DR-TB patients from 10 January 2013 to 27 December 2021, were reviewed using structured checklists. Data were entered into Epidata 3.1 version and exported to STATA 14 version for analysis. The outcome variables were Initial Sputum conversion (converted vs. not-converted) and treatment outcome (Unfavorable vs. Favorable). Sputum examination was performed using both Acid-fast bacillus (AFB) smear microscopy and Löwenstein-Jensen (LJ) culture technique. A binary logistic regression analysis was used to assess the association of independent variables with the first month sputum smear conversion, while a conditional logistic regression model was used to assess the association of treatment outcome with explanatory variables. The associations were reported using adjusted odds ratios (AORs) at a 95% confidence interval. A total of 273 DR-TB patients were included in this study. The unfavorable DR-TB treatment outcome was significantly associated with the history of chewing khat (AOR = 4.38, 95% CI = 1.62, 11.84), having bilateral lung cavity on baseline chest X-ray (AOR = 12.08, 95% CI = 1.80, 2.57), having greater than 2+ smear result at baseline (AOR = 3.79, 95% CI = 1.35, 10.59), and poor adherence (AOR = 2.9, 95% CI = 1.28, 6.82). The sputum smear non-conversion at first month was significantly associated with being Human Immune Virus (HIV)-negative (AOR = 0.37, 0.17, 0.82), having low baseline BMI (AOR = 0.54, 95% CI = 0.29, 0.97), baseline culture > 2++ (AOR = 0.15, 95% CI = 0.05, 0.49) and having greater than 2+ sputum smear result (AOR = 0.09, 95% CI = 0.012, 0.67). Patients with normal chest X-ray at baseline had 3.8 times higher chance of sputum smear conversion on first month (AOR = 3.77, 1.11, 12.77). The overall initial sputum smear conversion and the treatment success rate among DR-TB patients were 52.75 and 66.30%, respectively. The Baseline underweight, HIV-negative, baseline smear > 2+, baseline culture > 2++, and clear lung on baseline X-ray were associated with smear conversion and history of khat chewing, bilateral lung cavity at baseline, having greater than 2+ smear results at baseline, and patients with poor treatment adherence had hostile treatment outcomes. So, strengthening and implementing nutrition assessment and patient counseling during directly observed therapies (DOTs) service and drug compliance could result in early sputum conversion and better treatment outcomes. DR-TB patients with high bacterial load and abnormal lungs on radiologic examination at baseline could need special attention during their course of treatment.

Sections du résumé

Background UNASSIGNED
Drug-resistant tuberculosis (DR-TB) has become a public health problem throughout the world and about one-third of deaths were attributed to DR-TB from antimicrobial resistance which contributes to 10% of all TB deaths. Sub-Saharan Africa, particularly Ethiopia accounts for a significant number of TB cases. However, the scanty evidence on DR-TB contributing factors could affect the level of this deadly case tackling program. Therefore, this study aimed to assess the factors affecting sputum smear conversion and treatment outcomes among patients with DR-TB in Health facilities in Eastern Ethiopia.
Methods and materials UNASSIGNED
A cross-sectional study design was employed from 10 October to 10 November 2021, in the health facilities providing DR-TB services in Harari Region and Dire Dawa city administration. The medical records of 273 DR-TB patients from 10 January 2013 to 27 December 2021, were reviewed using structured checklists. Data were entered into Epidata 3.1 version and exported to STATA 14 version for analysis. The outcome variables were Initial Sputum conversion (converted vs. not-converted) and treatment outcome (Unfavorable vs. Favorable). Sputum examination was performed using both Acid-fast bacillus (AFB) smear microscopy and Löwenstein-Jensen (LJ) culture technique. A binary logistic regression analysis was used to assess the association of independent variables with the first month sputum smear conversion, while a conditional logistic regression model was used to assess the association of treatment outcome with explanatory variables. The associations were reported using adjusted odds ratios (AORs) at a 95% confidence interval.
Results UNASSIGNED
A total of 273 DR-TB patients were included in this study. The unfavorable DR-TB treatment outcome was significantly associated with the history of chewing khat (AOR = 4.38, 95% CI = 1.62, 11.84), having bilateral lung cavity on baseline chest X-ray (AOR = 12.08, 95% CI = 1.80, 2.57), having greater than 2+ smear result at baseline (AOR = 3.79, 95% CI = 1.35, 10.59), and poor adherence (AOR = 2.9, 95% CI = 1.28, 6.82). The sputum smear non-conversion at first month was significantly associated with being Human Immune Virus (HIV)-negative (AOR = 0.37, 0.17, 0.82), having low baseline BMI (AOR = 0.54, 95% CI = 0.29, 0.97), baseline culture > 2++ (AOR = 0.15, 95% CI = 0.05, 0.49) and having greater than 2+ sputum smear result (AOR = 0.09, 95% CI = 0.012, 0.67). Patients with normal chest X-ray at baseline had 3.8 times higher chance of sputum smear conversion on first month (AOR = 3.77, 1.11, 12.77).
Conclusion UNASSIGNED
The overall initial sputum smear conversion and the treatment success rate among DR-TB patients were 52.75 and 66.30%, respectively. The Baseline underweight, HIV-negative, baseline smear > 2+, baseline culture > 2++, and clear lung on baseline X-ray were associated with smear conversion and history of khat chewing, bilateral lung cavity at baseline, having greater than 2+ smear results at baseline, and patients with poor treatment adherence had hostile treatment outcomes. So, strengthening and implementing nutrition assessment and patient counseling during directly observed therapies (DOTs) service and drug compliance could result in early sputum conversion and better treatment outcomes. DR-TB patients with high bacterial load and abnormal lungs on radiologic examination at baseline could need special attention during their course of treatment.

Identifiants

pubmed: 36530886
doi: 10.3389/fmed.2022.1007757
pmc: PMC9751062
doi:

Types de publication

Journal Article

Langues

eng

Pagination

1007757

Informations de copyright

Copyright © 2022 Gamachu, Deressa, Birhanu, Ayana, Raru, Negash, Merga, Alemu, Ahmed, Mohammed, Abdulahi and Regassa.

Déclaration de conflit d'intérêts

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Références

Eur J Med Res. 2021 Apr 3;26(1):31
pubmed: 33812390
Infect Drug Resist. 2021 Oct 28;14:4493-4500
pubmed: 34737589
Ther Clin Risk Manag. 2016 Jan 06;12:41-6
pubmed: 26792994
Med Glas (Zenica). 2020 Aug 1;17(2):356-362
pubmed: 32662614
J Pharm Policy Pract. 2017 Dec 01;10:36
pubmed: 29214026
PLoS One. 2007 Nov 07;2(11):e1126
pubmed: 17987113
Int J Infect Dis. 2020 Sep;98:420-439
pubmed: 32645375
BMC Infect Dis. 2019 May 24;19(1):464
pubmed: 31126246
PLoS One. 2018 Apr 11;13(4):e0193903
pubmed: 29641576
BMC Infect Dis. 2010 Jul 16;10:210
pubmed: 20637077
PLoS One. 2015 Apr 07;10(4):e0123749
pubmed: 25849516
Thorax. 2010 Oct;65(10):863-9
pubmed: 20861290
Int J Infect Dis. 2022 Nov;124 Suppl 1:S26-S29
pubmed: 35321845
PLoS One. 2018 Jun 21;13(6):e0199320
pubmed: 29927980
PLoS One. 2022 Feb 17;17(2):e0262318
pubmed: 35176035
PLoS One. 2018 Jun 26;13(6):e0198080
pubmed: 29944658
PLoS One. 2017 Sep 25;12(9):e0185105
pubmed: 28945771
Saudi Med J. 2002 Jul;23(7):850-3
pubmed: 12174239
Lancet. 2022 Feb 12;399(10325):629-655
pubmed: 35065702
Quant Imaging Med Surg. 2018 Mar;8(2):161-173
pubmed: 29675357
Iran J Med Sci. 2016 Jan;41(1):44-7
pubmed: 26722144
Indian J Community Med. 2018 Apr-Jun;43(2):117-119
pubmed: 29899612
Am J Trop Med Hyg. 2018 Jun;98(6):1629-1636
pubmed: 29611497
Lancet Infect Dis. 2020 Jun;20(6):e117-e128
pubmed: 32482293
PLoS One. 2014 Sep 19;9(9):e108035
pubmed: 25238411
BMC Infect Dis. 2015 Mar 21;15:139
pubmed: 25884844
Infect Drug Resist. 2020 Jul 27;13:2547-2556
pubmed: 32821129
Medicine (Baltimore). 2020 Dec 11;99(50):e23649
pubmed: 33327347
J Med Assoc Thai. 2013 Jun;96(6):644-9
pubmed: 23951819
J Infect Dev Ctries. 2021 Sep 29;15(9.1):66S-74S
pubmed: 34609962
BMC Infect Dis. 2021 Mar 5;21(1):238
pubmed: 33663408
Infect Drug Resist. 2021 Apr 08;14:1343-1355
pubmed: 33854347
Int J Tuberc Lung Dis. 2016 Dec;20(12):1671-1676
pubmed: 27931345
BMC Infect Dis. 2018 Mar 5;18(1):104
pubmed: 29506480
Infect Drug Resist. 2021 Jun 30;14:2449-2460
pubmed: 34234475
Int J Tuberc Lung Dis. 2006 Apr;10(4):402-8
pubmed: 16602404
BMC Pulm Med. 2021 Apr 8;21(1):118
pubmed: 33832466
PLoS One. 2013 Sep 06;8(9):e73975
pubmed: 24040132
Trop Dis Travel Med Vaccines. 2018 Jun 14;4:5
pubmed: 29942536
Infect Drug Resist. 2018 Jan 23;11:147-154
pubmed: 29416359
PLoS One. 2018 May 23;13(5):e0197880
pubmed: 29791488

Auteurs

Mulugeta Gamachu (M)

School of Medicine, College of Health and Medical Sciences, Haramaya University, Harar, Ethiopia.
Department of Public Health, Rift Valley University, Harar, Ethiopia.

Alemayehu Deressa (A)

School of Public Health, College of Health and Medical Sciences, Haramaya University, Harar, Ethiopia.

Abdi Birhanu (A)

School of Medicine, College of Health and Medical Sciences, Haramaya University, Harar, Ethiopia.

Galana Mamo Ayana (GM)

School of Public Health, College of Health and Medical Sciences, Haramaya University, Harar, Ethiopia.

Temam Beshir Raru (TB)

School of Public Health, College of Health and Medical Sciences, Haramaya University, Harar, Ethiopia.

Belay Negash (B)

School of Public Health, College of Health and Medical Sciences, Haramaya University, Harar, Ethiopia.

Bedasa Taye Merga (BT)

School of Public Health, College of Health and Medical Sciences, Haramaya University, Harar, Ethiopia.

Addisu Alemu (A)

School of Public Health, College of Health and Medical Sciences, Haramaya University, Harar, Ethiopia.

Fila Ahmed (F)

School of Public Health, College of Health and Medical Sciences, Haramaya University, Harar, Ethiopia.

Ahmed Mohammed (A)

Department of Public Health, Rift Valley University, Harar, Ethiopia.

Ibsa M Abdulahi (IM)

School of Public Health, College of Health and Medical Sciences, Haramaya University, Harar, Ethiopia.

Lemma Demissei Regassa (LD)

School of Public Health, College of Health and Medical Sciences, Haramaya University, Harar, Ethiopia.

Classifications MeSH